Back to news

Neuronetics Reports Second Quarter 2026 Financial and Operating Results

Globe Newswire•11/08/2026•07:50 ET
0
Whiz Insights

MALVERN, Pa., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced its financial and operating results for the second quarter of 2026.

Second Quarter 2026 Financial Highlights * Total revenue of $41.6 million, up 9.1% compared to the second quarter of 2025 * Greenbrook revenue of $26.9 million, up 16.8% compared to the second quarter of 2025 * Adjusted EBITDA of $0.3 million compared to a loss of $5.6 million in the second quarter of 2025 * Net loss of $3.4 million compared to a loss of $10.1 million in the second quarter of 2025 * Net cash used in operations and investing of $1.4 million, a reduction of $2.3 million compared to $3.8 million in the second quarter of 2025 Recent Operational Highlights * Nir Naor appointed as Executive Vice President, Chief Financial Officer, Corporate Secretary, and Treasurer * Cory Anderson promoted to Executive Vice President/General Manager of Greenbrook clinics * Rob Greene appointed as Senior Vice President, Sales "This was a quarter of real operational progress, and meaningful steps toward our goal of sustained profitability and positive net cash flow from operations and investing," said Dan Reuvers, President and Chief Executive Officer of Neuronetics. "For some time, NeuroStar has not competed to its full potential, and we are changing that by broadening how customers can access our technology while we continue to drive operational gains across the Greenbrook clinics. We also strengthened our leadership team, adding proven talent in key roles. The combination of a leading TMS platform and a national care network is what sets Neuronetics apart, and it positions us to lead as new interventional therapies come to market. There is more work ahead, but I am encouraged by the traction we are beginning to demonstrate."

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in